About AbbVie (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ABBV
- CUSIP: 00287Y10
- Web: www.abbvie.com
Capitalization:- Market Cap: $153.79828 billion
- Outstanding Shares: 1,594,094,000
Average Prices:- 50 Day Moving Avg: $88.06
- 200 Day Moving Avg: $73.89
- 52 Week Range: $55.06 - $98.26
P/E:- Trailing P/E Ratio: 23.64
- Foreward P/E Ratio: 14.54
- P/E Growth: 1.24
Sales & Book Value:- Annual Revenue: $26.71 billion
- Price / Sales: 5.74
- Book Value: $3.77 per share
- Price / Book: 25.49
Dividend:- Annual Dividend: $2.56
- Dividend Yield: 2.7%
Profitability:- EBITDA: $11.57 billion
- Net Margins: 24.77%
- Return on Equity: 150.27%
- Return on Assets: 12.52%
Debt:- Debt-to-Equity Ratio: 5.63%
- Current Ratio: 1.38%
- Quick Ratio: 1.25%
Misc:- Average Volume: 6.45 million shs.
- Beta: 1.51
- Short Ratio: 5.37
Frequently Asked Questions for AbbVie (NYSE:ABBV)
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Friday, September 8th. Shareholders of record on Friday, October 13th will be given a dividend of $0.64 per share on Wednesday, November 15th. This represents a $2.56 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend is Thursday, October 12th. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its board has approved a share buyback program on Sunday, April 9th 2017, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 5% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Friday, July, 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.40 by $0.02. The firm earned $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company's revenue was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 EPS. View AbbVie's Earnings History.
When will AbbVie make its next earnings announcement?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY17 earnings guidance on Friday, July, 28th. The company provided EPS guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?
16 brokers have issued 12 month price targets for AbbVie's stock. Their predictions range from $60.00 to $115.00. On average, they anticipate AbbVie's share price to reach $93.33 in the next year. View Analyst Ratings for AbbVie.
What are analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and should continue to do well. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Meanwhile, AbbVie has promising pipeline with several pivotal data readouts and regulatory milestones due in the second half. Maviret, approved recently, has the potential to rejuvenate AbbVie’s struggling HCV franchise. AbbVie’s shares have outperformed the industry this year so far. However, though Humira is doing well, the company is concerned about the product’s long-term growth prospects, given the potential biosimilar competition. Viekira also faces intense pricing and competitive pressure in the HCV market. Estimates have gone up slightly ahead of the company’s Q3 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters." (10/20/2017)
- 2. UBS AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
- 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Advanced Accelerator Applications S.A. (AAAP), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), CorMedix (CRMD), Check-Cap (CHEK), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
- William J. Chase, Executive Vice President, Chief Financial Officer
- Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
- Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
- Carlos Alban, Executive Vice President - Commercial Operations
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
- Timothy J. Richmond, Senior Vice President - Human Resources
- Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
- Robert A. Michael, Vice President, Controller
- Robert J. Alpern M.D., Independent Director
Who owns AbbVie stock?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional investors include APG Asset Management N.V. (0.12%), PGGM Investments (0.09%), Robeco Institutional Asset Management B.V. (0.06%), State Treasurer State of Michigan (0.04%), Fisher Asset Management LLC (0.04%) and Assenagon Asset Management S.A. (0.04%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Sit Investment Associates Inc., Sabal Trust CO, Bridges Investment Counsel Inc., Meeder Asset Management Inc., LS Investment Advisors LLC, Verde Servicos Internacionais S.A. and Private Asset Management Inc.. Company insiders that have sold AbbVie stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., APG Asset Management N.V., PGGM Investments, Barometer Capital Management Inc., Shell Asset Management Co., Ingalls & Snyder LLC, Glynn Capital Management LLC and Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for AbbVie.
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of AbbVie stock can currently be purchased for approximately $96.10.
MarketBeat Community Rating for AbbVie (NYSE ABBV)MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.63) |
| Consensus Price Target: | $93.33 (2.88% downside) |
Consensus Price Target History for AbbVie (NYSE:ABBV)
Analysts' Ratings History for AbbVie (NYSE:ABBV)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/16/2017 | Jefferies Group LLC | Boost Price Target | Buy | $107.00 -> $115.00 | N/A |  |
| 10/13/2017 | Barclays PLC | Boost Price Target | Equal Weight | $90.00 | N/A | |
| 10/11/2017 | Cowen and Company | Upgrade | Market Perform -> Outperform | $91.17 -> $105.00 | N/A | |
| 10/2/2017 | Leerink Swann | Upgrade | Market Perform -> Outperform | $89.00 -> $106.00 | Medium | |
| 10/1/2017 | Credit Suisse Group | Reiterated Rating | Neutral | $74.00 -> $94.00 | Medium | |
| 9/30/2017 | Evercore ISI | Reiterated Rating | Outperform | $95.00 -> $100.00 | Medium | |
| 9/28/2017 | BMO Capital Markets | Reiterated Rating | Hold | $66.00 | Low | |
| 9/29/2017 | Argus | Boost Price Target | Buy | $90.00 -> $110.00 | Low | |
| 9/29/2017 | Morgan Stanley | Boost Price Target | Equal Weight | $70.00 -> $95.00 | Low | |
| 9/28/2017 | Deutsche Bank AG | Boost Price Target | Hold | $88.00 | Low | |
| 9/15/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $100.00 | High | |
| 9/13/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | $95.00 | Low | |
| 9/8/2017 | Goldman Sachs Group Inc | Reiterated Rating | Buy | $85.00 -> $100.00 | Low | |
| 6/22/2017 | Societe Generale | Upgrade | Hold -> Buy | | Low | |
| 12/8/2016 | William Blair | Reiterated Rating | Outperform | $76.00 | N/A | |
| 11/28/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | $60.00 | N/A | |
| 9/8/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | $75.00 -> $73.00 | N/A | |
| 9/1/2016 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $82.00 | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Neutral | $59.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for AbbVie (NYSE:ABBV)Earnings History by Quarter for AbbVie (NYSE ABBV)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/27/2017 | | $1.38 | | | | | N/A | |
| 7/28/2017 | Q2 2017 | $1.40 | $1.42 | $6.93 billion | $6.94 billion | View | N/A | |
| 4/27/2017 | Q1 2017 | $1.26 | $1.28 | $6.49 billion | $6.54 billion | View | N/A | |
| 1/27/2017 | Q416 | $1.20 | $1.20 | $6.92 billion | $6.78 billion | View | Listen | |
| 10/28/2016 | Q316 | $1.21 | $1.21 | $6.55 billion | $6.43 billion | View | Listen | |
| 7/29/2016 | Q216 | $1.20 | $1.26 | $6.20 billion | $6.43 billion | View | Listen | |
| 4/28/2016 | Q116 | $1.14 | $1.15 | $6.03 billion | $5.96 billion | View | Listen | |
| 1/29/2016 | Q415 | $1.12 | $1.13 | $6.41 billion | $6.36 billion | View | Listen | |
| 10/30/2015 | Q315 | $1.08 | $1.13 | $5.90 billion | $4.94 billion | View | Listen | |
| 7/24/2015 | Q215 | $1.06 | $1.08 | $5.60 billion | $5.48 billion | View | Listen | |
| 4/23/2015 | Q115 | $0.85 | $0.94 | $718.50 million | $5.04 billion | View | Listen | |
| 1/30/2015 | Q414 | $0.86 | $0.89 | $5.34 billion | $5.45 billion | View | Listen | |
| 10/31/2014 | Q3 | $0.77 | $0.89 | $4.82 million | $5.02 million | View | Listen | |
| 7/25/2014 | Q214 | $0.76 | $0.82 | $4.70 billion | $4.93 billion | View | Listen | |
| 4/25/2014 | Q114 | $0.68 | $0.71 | $4.33 billion | $4.56 billion | View | Listen | |
| 1/31/2014 | Q413 | $0.82 | $0.82 | $5.10 billion | $5.11 billion | View | Listen | |
| 10/25/2013 | Q313 | $0.78 | $0.82 | $4.52 billion | $4.66 billion | View | Listen | |
| 7/26/2013 | Q2 2013 | $0.79 | $0.92 | $4.54 billion | $4.69 billion | View | Listen | |
| 4/26/2013 | Q1 2013 | $0.67 | $0.68 | $4.17 billion | $4.33 billion | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AbbVie (NYSE:ABBV)Current Year EPS Consensus Estimate: $5.53 EPS
Next Year EPS Consensus Estimate: $6.61 EPS
Current Dividend Information for AbbVie (NYSE:ABBV)| Next Dividend: | 11/15/2017 |
| Annual Dividend: | $2.56 |
| Dividend Yield: | 2.66% |
| Dividend Growth: | 12.50% (3 Year Average) |
| Payout Ratio: | 62.90% (Trailing 12 Months of Earnings)
46.29% (Based on This Year's Estimates)
38.73% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for AbbVie (NYSE ABBV)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 9/8/2017 | Quarterly | $0.64 | 2.94% | 10/12/2017 | 10/13/2017 | 11/15/2017 |
| 6/23/2017 | quarterly | $0.64 | 3.52% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.64 | 4.14% | 4/11/2017 | 4/13/2017 | 5/15/2017 |
| 10/28/2016 | quarterly | $0.64 | 4.44% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/12/2016 | quarterly | $0.57 | 3.56% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/17/2016 | quarterly | $0.57 | 3.8% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.57 | 4.2% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 11/2/2015 | quarterly | $0.57 | 3.6% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/14/2015 | quarterly | $0.51 | 3.46% | 10/13/2015 | 10/15/2015 | 11/14/2015 |
| 6/19/2015 | quarterly | $0.51 | 2.94% | 7/13/2015 | 7/15/2015 | 8/14/2015 |
| 2/20/2015 | quarterly | $0.51 | 3.33% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 10/20/2014 | quarterly | $0.49 | 3.48% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/19/2014 | quarterly | $0.42 | 2.86% | 10/10/2014 | 10/15/2014 | 11/17/2014 |
| 6/19/2014 | quarterly | $0.42 | 3.15% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/20/2014 | quarterly | $0.42 | 3.29% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 12/12/2013 | quarterly | $0.40 | 3.06% | 1/13/2014 | 1/15/2014 | 2/14/2014 |
| 9/19/2013 | quarterly | $0.40 | 3.34% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/20/2013 | quarterly | $0.40 | 3.75% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.40 | 4.19% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 1/7/2013 | special | $0.40 | | 1/11/2013 | 1/15/2013 | 2/15/2013 |
| 1/4/2013 | quarterly | $0.40 | | | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.25%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/28/2017 | Robert A Michael | VP | Sell | 6,699 | $88.00 | $589,512.00 | |
| 9/11/2017 | Azita Saleki-Gerhardt | SVP | Sell | 8,300 | $85.02 | $705,666.00 | |
| 8/7/2017 | Richard A Gonzalez | Chairman | Sell | 193,131 | $71.00 | $13,712,301.00 | |
| 8/4/2017 | Richard A Gonzalez | Chairman | Sell | 87,899 | $71.02 | $6,242,586.98 | |
| 8/3/2017 | Richard A Gonzalez | CEO | Sell | 65,861 | $71.00 | $4,676,131.00 | |
| 7/31/2017 | Edward J Rapp | Director | Buy | 4,000 | $70.45 | $281,800.00 | |
| 7/31/2017 | Henry O Gosebruch | Insider | Sell | 18,000 | $70.09 | $1,261,620.00 | |
| 6/14/2017 | Carlos Alban | EVP | Sell | 45,800 | $70.00 | $3,206,000.00 | |
| 6/14/2017 | Laura J Schumacher | Insider | Sell | 79,800 | $70.00 | $5,586,000.00 | |
| 5/19/2017 | Richard A Gonzalez | Chairman | Sell | 71,235 | $65.49 | $4,665,180.15 | |
| 5/18/2017 | William J Chase | CFO | Sell | 38,300 | $65.35 | $2,502,905.00 | |
| 5/4/2017 | Carlos Alban | EVP | Sell | 43,000 | $67.00 | $2,881,000.00 | |
| 3/10/2017 | Laura J Schumacher | Insider | Sell | 40,000 | $65.26 | $2,610,400.00 | |
| 3/10/2017 | Robert A Michael | VP | Sell | 5,132 | $65.29 | $335,068.28 | |
| 3/10/2017 | Timothy J Richmond | SVP | Sell | 22,451 | $65.29 | $1,465,825.79 | |
| 3/8/2017 | Richard A Gonzalez | Chairman | Sell | 72,016 | $64.25 | $4,627,028.00 | |
| 12/2/2016 | William J Chase | CFO | Sell | 6,600 | $59.19 | $390,654.00 | |
| 9/7/2016 | Laura J Schumacher | Insider | Sell | 50,000 | $65.00 | $3,250,000.00 | |
| 6/24/2016 | Laura J Schumacher | EVP | Sell | 186,106 | $60.03 | $11,171,943.18 | |
| 6/2/2016 | Richard A Gonzalez | CEO | Sell | 285,953 | $63.82 | $18,249,520.46 | |
| 5/11/2016 | Richard A Gonzalez | CEO | Sell | 39,000 | $63.80 | $2,488,200.00 | |
| 5/10/2016 | Carlos Alban | EVP | Sell | 47,438 | $63.52 | $3,013,261.76 | |
| 5/10/2016 | Thomas A Hurwich | VP | Sell | 6,000 | $63.59 | $381,540.00 | |
| 5/10/2016 | Timothy J Richmond | SVP | Sell | 21,583 | $63.52 | $1,370,952.16 | |
| 3/8/2016 | Laura J Schumacher | EVP | Sell | 25,000 | $56.09 | $1,402,250.00 | |
| 3/1/2016 | Timothy J Richmond | SVP | Sell | 12,866 | $55.05 | $708,273.30 | |
| 4/28/2015 | Richard A Gonzalez | CEO | Sell | 102,964 | $64.67 | $6,658,681.88 | |
| 3/2/2015 | Laura J Schumacher | EVP | Sell | 25,000 | $60.30 | $1,507,500.00 | |
| 3/2/2015 | Timothy J Richmond | SVP | Sell | 14,388 | $60.33 | $868,028.04 | |
| 12/22/2014 | William J Chase | CFO | Sell | 8,495 | $68.00 | $577,660.00 | |
| 3/4/2014 | Richard Gonzalez | CEO | Sell | 4,799 | $51.20 | $245,708.80 | |
| 3/3/2014 | Azita Saleki-Gerhardt | SVP | Sell | 2,443 | $50.25 | $122,760.75 | |
| 3/3/2014 | Carlos Alban | EVP | Sell | 2,882 | $50.09 | $144,359.38 | |
| 3/3/2014 | William Chase | CFO | Sell | 3,948 | $50.22 | $198,268.56 | |
| 9/17/2013 | Azita Saleki-Gerhardt | SVP | Sell | 10,473 | $45.84 | $480,082.32 | |
| 8/19/2013 | Azita Saleki-Gerhardt | SVP | Sell | 1,270 | $43.01 | $54,622.70 | |
| 8/12/2013 | Azita Saleki-Gerhardt | SVP | Sell | 8,851 | $44.91 | $397,498.41 | |
| 3/11/2013 | Edward J Rapp | Director | Buy | 2,500 | $37.67 | $94,175.00 | |
| 2/4/2013 | Frederick H Waddell | Director | Buy | 2,000 | $37.05 | $74,100.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
| Source: |
|
| Date | Headline |
|---|
 | Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics - Nasdaq
www.nasdaq.com - October 20 at 8:34 PM |
 | Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics
finance.yahoo.com - October 20 at 8:34 PM |
| LS Investment Advisors, LLC Buys DowDuPont Inc, iShares Edge MSCI Min Vol Emerging Markets, ...
www.nasdaq.com - October 20 at 3:29 PM |
| Catch This Falling Knife — Go Long Celgene Corporation
finance.yahoo.com - October 20 at 3:29 PM |
| AbbVie Stock: Performance in 3Q17
finance.yahoo.com - October 20 at 3:29 PM |
 | AbbVie Inc. (ABBV) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 20 at 1:47 PM |
| AbbVie Inc. (ABBV) Scheduled to Post Quarterly Earnings on Friday
www.americanbankingnews.com - October 20 at 1:08 AM |
 | BRIEF-Abbvie and harpoon therapeutics announce immuno-oncology research collaboration
www.reuters.com - October 19 at 3:17 PM |
| AbbVie to Present at the 2017 Credit Suisse Health Care Conference
finance.yahoo.com - October 19 at 3:17 PM |
| 3 Top Stocks Billionaires Love
finance.yahoo.com - October 19 at 3:17 PM |
| Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
finance.yahoo.com - October 19 at 3:17 PM |
| AbbVie Inc. (ABBV) Expected to Announce Quarterly Sales of $7.06 Billion
www.americanbankingnews.com - October 19 at 10:04 AM |
| AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
finance.yahoo.com - October 18 at 3:29 PM |
| Bulls bet on two key Dow stocks. Plus, financials could b...
finance.yahoo.com - October 18 at 3:29 PM |
| Micron, Abbvie, Sherwin-Williams, Wynn Resorts & Exxon
finance.yahoo.com - October 18 at 3:29 PM |
 | Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie
feeds.benzinga.com - October 18 at 8:55 AM |
| Where to Find Value in Healthcare Stocks
finance.yahoo.com - October 17 at 8:19 PM |
| Kessler Investment Group, LLC Buys Apple Inc, The Home Depot Inc, Amazon. ...
www.nasdaq.com - October 17 at 3:17 PM |
| J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
finance.yahoo.com - October 17 at 3:17 PM |
| Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
finance.yahoo.com - October 17 at 3:17 PM |
| Analysts Anticipate AbbVie Inc. (ABBV) Will Post Earnings of $1.38 Per Share
www.americanbankingnews.com - October 17 at 6:28 AM |
 | AbbVie (ABBV) a Buy on Healthy Earnings Momentum
investorplace.com - October 16 at 1:22 PM |
| AbbVie Inc. (ABBV) Rating Increased to Outperform at Cowen and Company
www.americanbankingnews.com - October 16 at 12:50 AM |
 | Better Buy: AbbVie Inc. vs. Merck -- The Motley Fool - Motley Fool
www.fool.com - October 15 at 1:22 AM |
| Better Buy: AbbVie Inc. vs. Merck
finance.yahoo.com - October 14 at 8:19 PM |
| AbbVie Inc. (ABBV) Receives "Neutral" Rating from UBS AG
www.americanbankingnews.com - October 13 at 10:44 PM |
| Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?
finance.yahoo.com - October 13 at 8:23 PM |
| New Law May Pressure Drug Prices
finance.yahoo.com - October 13 at 8:23 PM |
| Why 2017 Could Be This Stock's Best Year Yet
finance.yahoo.com - October 13 at 8:23 PM |
| AbbVie Inc. (ABBV) PT Raised to $90.00 at Barclays PLC
www.americanbankingnews.com - October 13 at 7:34 PM |
| Fundamental Equity Analysis – Consolidated Research on Johnson & Johnson, Home Depot, Adobe, Disney, AbbVie, and eBay – Developing Opportunities, Future Expectations, and Projections
finance.yahoo.com - October 13 at 3:18 PM |
| Cancer Space Update: Lung & Breast Cancer Studies in Focus
finance.yahoo.com - October 13 at 3:18 PM |
| 4 things that might surprise investors this earnings season
finance.yahoo.com - October 13 at 3:18 PM |
| AbbVie, Abbott duck Depakote off-label marketing case on appeal - Reuters
www.reuters.com - October 12 at 8:21 PM |
| Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock? - Nasdaq
www.nasdaq.com - October 12 at 3:18 PM |
| AbbVie Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - October 12 at 3:18 PM |
| Top 5 Biotech Stocks for 2017
finance.yahoo.com - October 12 at 3:18 PM |
| AbbVie: You're Upgrading It…Now?
finance.yahoo.com - October 11 at 8:29 PM |
| Is AbbVie the Best Dividend Stock in Healthcare?
finance.yahoo.com - October 11 at 8:29 PM |
| How Safe Is AbbVie's Dividend?
finance.yahoo.com - October 11 at 8:29 PM |
| How Safe Is AbbVie's Dividend?
www.fool.com - October 11 at 7:40 PM |
 | Hurricane-related damage could cause shortages of 40 drugs - FDA - Seeking Alpha
seekingalpha.com - October 11 at 3:27 PM |
| AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 12, 2017 - Nasdaq
www.nasdaq.com - October 11 at 3:26 PM |
| BRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
www.reuters.com - October 10 at 8:19 PM |
| 3 Healthcare Dividend Stocks Ideal for Retirees
finance.yahoo.com - October 10 at 8:19 PM |
| AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology
finance.yahoo.com - October 10 at 8:19 PM |
| Hold Recommendation for AbbVie (ABBV) Stock Kept - Investorplace.com
investorplace.com - October 10 at 3:19 PM |
| California enacts law aimed at corralling high drug prices - Seeking Alpha
seekingalpha.com - October 10 at 3:19 PM |
| Ex-Dividend Reminder: Foot Locker, Patterson Companies and AbbVie - Nasdaq
www.nasdaq.com - October 10 at 3:19 PM |
| AbbVie (ABBV) and Its Competitors Head to Head Comparison
www.americanbankingnews.com - October 9 at 6:28 PM |
AbbVie (ABBV) Chart for Saturday, October, 21, 2017
